- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04515732
Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP) (DANPAPP)
Prevalence, Pattern and Disease Course og Arthritis and Enthesitis in Patients With Psoriasis, and Effect of Apremilast in Subclinical, US-defined Psoriatic Arthritis - a Population Based Study Applying Clinical, Ultrasonic, MRI and Patient-reported Outcomes
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
Part 1:
A population-based survey of Danish inhabitants, will by screening of approximately 10.000 Danes identify approximately 425 persons who report to have psoriasis(PsO) with or without psoriatic arthritis (PsA). These will receive an e-mail invitation to an internet based questionnaire regarding demographics, skin and joint complaints, diagnosed diseases, contact to health care providers, and different aspect of psychological and physical function and wellbeing (incl. function, health-related quality of life, depression, anxiety, social participation, and sleep disturbances). In the questionnaire the participant will be asked if he/she would be interested in participating in a clinical study.
Part 2:
Participants who accept the above mentioned invitation (estimated 273) will be seen in a Department of Rheumatology, for the following examination programme: Clinical examination with a focus on skin, joints and entheses,ultrasonic (US) examination of joints and entheses, patient-reported outcomes and blood sampling for both stratification and identification of biochemical signs of inflammation.
Patients with musculoskeletal pain and certain joint and/or entheseal inflammation documented by US, will be invited to participate in a 12 months' interventional study (part 3a, below), whereas patients without musculoskeletal pain but with US findings (as above) will be invited to participate in a 12 months non-interventional follow-up study (part 3b, below). Patients with pre-diagnosed PsA that by US have active inflammation (same definition and criteria as above), will also be invited to participate in the interventional study if they fit the criteria, especially those described under concomitant medication, otherwise they will be offered to participate in the non-interventional study.
Part 3a:
Patients with musculoskeletal pain in relation to joints and/or entheses (that is not explained by alternative diagnosis, as assessed by including rheumatologist) and "US-defined PsA", i.e. with certain joint and/or entheseal inflammation as documented by US, will be offered inclusion in a 12 months' interventional study, in which 6 month induction therapy with apremilast (in addition to their usual therapy) will be followed by cessation of apremilast and 6 months of observation. Patients will be followed with clinical examination, PRO's, blood sampling and US at months 3, 6, 9 and 12.
MRI will be performed at inclusion and at 6 months follow-up in selected patients (patients with dactylitis or with enthesitis in the ankle region (Achilles enthesitis or plantar fasciitis)).
Part 3b:
Patients without musculoskeletal pain but with certain joint or entheseal inflammation verified by US will be offered inclusion in a 12 months' non-interventional study. Patients will continue their current therapy and be followed with clinical examination, patient-reported outcomes, blood sampling and US at months 3, 6, 9 and 12.
Typ studiów
Zapisy (Oczekiwany)
Faza
- Faza 4
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Glostrup, Dania, 2600
- Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet Glostrup
-
Sønderborg, Dania, 6400
- Dansk Gigthospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
In general (all parts of the study):
- Age >18 years
- Being able and willing to comply with the requirements of this protocol
- Having signed informed consent
Part 2:
• Psoriasis, diagnosed by a physician according to patient
Part 3a:
- Musculoskeletal pain in relation to joints or entheses (that is not explained by alternative diagnosis, as assessed by including rheumatologist) and"US-defined PsA" (ie. with certain joint and/or entheseal inflammation as documented by US (see 'Definitions of patient populations' for definition))
MRI substudy:
- Clinical dactylitis or enthesitis in the ankle region (Achilles enthesitis or plantar fasciitis)
- No contraindications for MRI (see appendix 22.2.2) For allowed and disallowed previous and concomitant treatment, please see paragraph on "Previous and concomitant medication".
Part 3b:
• Not having musculoskeletal pain but still "US-defined PsA" (i.e. with certain joint and/or entheseal inflammation as documented by US (see 'Definitions of patient populations' for definition))
Exclusion Criteria:
In general (all parts of study):
• Incapability of complying with the examination program of this protocol for physical, mental or practical reasons.
Part 2:
• Incapability of understanding spoken or written danish.
Part 3a:
- Pregnancy, pregnancy wish or breast-feeding.
- Hypersensitivity to the active substance (apremilast) or any of the excipients.
- Hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose
- malabsorption
- Severe renal failure (glomerular filtration rate (GFR) <30ml/min)
- Current treatment with potent CYP3A4 enzyme inhibitors (rifampicin, phenobarbital, carbamazepin, phenytoin, perikon ("grønne lykkepiller" , Neurokan, Modigen, Calmigen, Velzina))
- Current or planned (during the study period) treatment that might cause psychiatric symptoms
- Known active tuberculosis (TB) or history of incompletely treated TB.
- Clinical history of serious liver disease.
- Hepatitis B antigen positivity or Hepatitis C antibodies positivity at screening (tests ≤3 months before inclusion is accepted).
- Bacterial infections requiring antibiotics (oral or intravenously) or serious viral or fungal infections within the last four weeks before screening. Treatment of such infections should be completed 4 weeks prior to screening.
- Clinical history of serious immunological disease (including HIV or other congenital or acquired immune disease) or other serious uncontrolled disease.
- Current depression, previous depression, previous suicidal thoughts/tendencies or psychiatric symptoms
- Conditions, including abnormal laboratory measurements, which might put the patient at an unnecessary risk by participation in the study or make data difficult to interpret.
- Known inflammatory rheumatic disease other than PsA.
- MRI substudy: Contraindications for MRI (see appendix 22.2.2)
- Certain previous and concomitant treatment
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Diagnostyczny
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: 3a (apremilast intervention)
Apremilast in standard dosis (gradual increase 0-30 mg x 2 daily over the first 6 days, hereafter 30 mg x 2 daily) for 6 months, followed by 6 months observation.
|
As in description
|
Brak interwencji: 3b (non-intervention)
Observation
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Number of participants with PsO reporting musculoskeletal pain within the past 12 months
Ramy czasowe: 1 day (At completion of questionnaire (performed once))
|
Part 1 - e-based questionnaire.
Number of patients reporting joint- or entheseal pain within the past 12 months
|
1 day (At completion of questionnaire (performed once))
|
The difference in number of joints with US defined synovitis, in PsO patients with, compared to patients without musculoskeletal pain.
Ramy czasowe: Day 0
|
Part 2 - cross sectional study
|
Day 0
|
The difference in number of entheses with US defined enthesitis, in PsO patients with, compared to patients without musculoskeletal pain.
Ramy czasowe: Day 0
|
Part 2 - cross sectional study
|
Day 0
|
Change in OMERACT-EULAR Global US score of synovitis, from baseline to 6 months, in patients treated with apremilast (intervention group).
Ramy czasowe: 6 months
|
Part 3 - follow up study
|
6 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
The correlations between presence of musculoskeletal pain and patient reported outcomes of function, health related quality of life, and impact on patient's lives (including EQ5D, HAQ and PsAID)
Ramy czasowe: 1 day (At completion of e-based questionnaire (performed once))
|
Part 1
|
1 day (At completion of e-based questionnaire (performed once))
|
The prevalence of US defined synovitis at the individual 48 joints sites in patients with compared to patients without musculoskeletal pain.
Ramy czasowe: Day 0
|
Part 2
|
Day 0
|
The prevalence of US defined enthesitis at the individual 12 entheseal sites in patients with compared to patients without musculoskeletal pain.
Ramy czasowe: Day 0
|
Part 2
|
Day 0
|
The correlation between clinical and US scores of synovitis and enthesitis with patient reported outcomes of pain, function and impact on patient's lives (including pain, HAQ and PsAID).
Ramy czasowe: Day 0
|
Part 2
|
Day 0
|
Sensitivity and specificity of screening questionnaires, with fulfillment of CASPAR criteria as gold standard, and "US defined PsA" as alternative.
Ramy czasowe: Day 0
|
Part 2
|
Day 0
|
Change in "US total count of inflamed joints and entheses" from baseline to 3, 6 and 12 months, and from 6 to 12 months, in intervention and non-intervention groups.
Ramy czasowe: 3, 6, 12 months
|
Part 3
|
3, 6, 12 months
|
Change in patient global pain on a visual analogue scale (VAS, range 0-100), from baseline to 6 months and from 6 to 12 months in intervention group.
Ramy czasowe: 0-6 months, 6-12 months
|
Part 3
|
0-6 months, 6-12 months
|
Change in OMERACT-EULAR Global US score of synovitis from baseline to 3 and 6 months, and from 6 to 12 months, in intervention and non-intervention groups.
Ramy czasowe: 0-3-6-12 months
|
Part 3
|
0-3-6-12 months
|
Change in US enthesitis activity score from baseline to 3, 6 and 12 months, and from 6 to 12 months, in intervention and non-intervention groups.
Ramy czasowe: 0-3-6-12 months
|
Part 3
|
0-3-6-12 months
|
Change in PRO's (including PsAID, HAQ) from baseline to 3, 6, 9 and 12 months.
Ramy czasowe: 0-3-6-9-12 months
|
Part 3
|
0-3-6-9-12 months
|
The correlation between changes in clinical and US scores of synovitis and enthesitis and changes in patient reported outcomes, overall and in intervention and non-intervention groups.
Ramy czasowe: 0-3-6-12 months
|
Part 3
|
0-3-6-12 months
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change in DAS28-CRP (Disease Activity Score, 28 joints, CRP) from baseline to month 3 and 6, and from month 6 to month 12.
Ramy czasowe: 0-3-6-12 months
|
Part 3
|
0-3-6-12 months
|
Change in PASDAS (Psoriatic Arthritis Disease Activity Score) from baseline to month 3 and 6, and from month 6 to month 12.
Ramy czasowe: 0-3-6-12 months
|
Part 3
|
0-3-6-12 months
|
Change in DAPSA (Disease Activity Index for Psoriatic Arthritis) from baseline to month 3 and 6, and from month 6 to month 12.
Ramy czasowe: 0-3-6-12 months
|
Part 3
|
0-3-6-12 months
|
Change in mCPDAI (modified Composite Psoriatic Disease Activity Index) from baseline to month 3 and 6, and from month 6 to month 12.
Ramy czasowe: 0-3-6-12 months
|
Part 3
|
0-3-6-12 months
|
Evaluation of EULAR response criteria from baseline to month 3 and 6, and from month 6 to month 12.
Ramy czasowe: 0-3-6-12 months
|
Part 3
|
0-3-6-12 months
|
Evaluation of ACR (American College of Rheumatology) response criteria from baseline to month 3 and 6, and from month 6 to month 12.
Ramy czasowe: 0-3-6-12 months
|
Part 3
|
0-3-6-12 months
|
Evaluation of PsARC (Psoriatic Arthritis Response Criteria) from baseline to month 3 and 6, and from month 6 to month 12.
Ramy czasowe: 0-3-6-12 months
|
Part 3
|
0-3-6-12 months
|
Współpracownicy i badacze
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby skórne
- Choroby stawów
- Choroby układu mięśniowo-szkieletowego
- Choroby skóry, grudkowo-łuskowate
- Choroby kręgosłupa
- Choroby kości
- Spondylartropatie
- Zapalenie stawów kręgosłupa
- Zapalenie stawów kręgosłupa
- Artretyzm
- Łuszczyca
- Zapalenie stawów, łuszczyca
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Agenty obwodowego układu nerwowego
- Inhibitory enzymów
- Środki przeciwbólowe
- Agenci systemu sensorycznego
- Środki przeciwzapalne, niesteroidowe
- Środki przeciwbólowe, nie narkotyczne
- Środki przeciwzapalne
- Środki przeciwreumatyczne
- Inhibitory fosfodiesterazy
- Inhibitory fosfodiesterazy 4
- Apremilast
Inne numery identyfikacyjne badania
- DANPAPP
- 2016-004354-15 (Numer EudraCT)
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Apremilast Oral Tablet
-
Istituto Oncologico Veneto IRCCSRekrutacyjnyGruczolakorak jelita grubegoWłochy
-
Raincy Montfermeil Hospital GroupJeszcze nie rekrutacja
-
Asian Institute of Gastroenterology, IndiaRekrutacyjny
-
Prince of Songkla UniversityZakończonyZapalenie błony śluzowej jamy ustnej
-
National University of MalaysiaZakończony
-
McMaster UniversityZakończony
-
Jiangsu HengRui Medicine Co., Ltd.Aktywny, nie rekrutujący
-
University of BrasiliaZakończonyPłytka nazębna | Próchnica zębów
-
Daewoong Pharmaceutical Co. LTD.NieznanyZdrowyRepublika Korei
-
Daewoong Pharmaceutical Co. LTD.NieznanyZdrowyRepublika Korei